Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE12 | Q6L8Q7 | 2/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 5/20 | 0.36 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446571 | 0.69 | PDE12 (1.00) | PDE12FASNKDM1A | |
| SCHEMBL3537456 | 0.57 | ITK (0.53) | PDE12PDE10A | |
| SCHEMBL13549069 | 0.57 | ITK (0.57) | PDE12 | |
| SCHEMBL22956068 | 0.56 | HPGD (0.53) | PADI4ADORA2A | |
| SCHEMBL17263216 | 0.56 | SMN1; SMN2 (0.49) | PDE10A | |
| SCHEMBL20918168 | 0.56 | RAB9A (0.55) | — | |
| SCHEMBL17896610 | 0.56 | CYP11B2 (0.53) | PDE10A | |
| SCHEMBL3534853 | 0.55 | FGFR1 (0.48) | PDE12ALK | |
| SCHEMBL3540234 | 0.55 | ITK (0.48) | PDE12 | |
| Oxalic Acid SCHEMBL7865005 | 0.55 | KDM4E (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118903419-A | Use of PDE inhibitors or salts thereof for the production of medicaments for the prophylaxis and/or treatment of gastrointestinal diseases | 广州市妇女儿童医疗中心 | 2024-11-08 | — | — | CN | disclosed |
| CN-113244395-B | Fibrotic disease mechanism and therapeutic agent thereof | 广州市妇女儿童医疗中心 | 2024-07-23 | — | — | CN | disclosed |
| US-20230111925-A1 | FIBROTIC DISEASE MECHANISM AND THERAPEUTIC DRUG THEREFOR | GUANGZHOU WOMEN AND CHILDREN'S MEDICAL CENTER (CN) | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230111925-A1 | FIBROTIC DISEASE MECHANISM AND THERAPEUTIC DRUG THEREFOR | PDE7B, PDE4B, PDE3B | PDE12 13/4885MC4R 3352/4885FASN 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.